Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders
Table 4
Scenario sensitivity analyses results.
No.
Variable
Base case input value
Sensitivity input value
ICER (Cost (RM) per QALY gained)
1a
Undiscounted cost and outcomes
3%
0%
48,033
1b
5% discount rate
3%
5%
47,419
2a
3-year time horizon
60 years
3 years
25,438
2b
10-year time horizon
60 years
10 years
47,586
3a
High sevelamer dose
2.184g
4.8g
65,210
3b
High CaCO3 dose
2.95g
7.5g
47,325
4
Low dialysis utility
0.8
0.72
51,086
5a
Low HD cost
RM259.09
RM197.48
40,627
5b
High HD cost
RM259.09
RM350.00
58,084
6
Exclude dialysis cost
RM259.09
0
14,407
We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.
